Treatment
Test Drug clinical trials
We’re tracking 124 recruiting studies that include Test Drug, each written for real people, not researchers, below.
Recruiting studies
- NCT06406660Recruiting
Organoid-guided drug selection for recurrent small cell lung cancer
This study uses a patient's own tumor cells grown in the lab (called an organoid) to find the most effective drug for recurrent small cell lung cancer. It aims to personalize treatment after standard therapy stops working.
Zhengzhou, HenanAges 18–75 - NCT06406608Recruiting
Personalized drug test for drug-resistant lung cancer
This trial tests a new way to choose your next treatment by growing a mini version of your tumor (an organoid) in a lab and seeing which drugs kill it best. It is for people with drug-resistant non-small cell lung cancer who have already tried at least two standard treatments.
Zhengzhou, HenanAges 18–75 - NCT05857969RecruitingPhase 1
Testing cancer drug response on removed tumor tissue
This early study uses tumor tissue (or bone marrow from blood cancers) and performs lab tests to see which cancer drugs may work better for each person. It also collects genetic information from blood or a saliva swab to help understand why cancers respond differently.
Miami, FloridaAges 1 day–21 years - NCT06971848Recruiting
Skin testing for biologic drug allergies
This trial checks if people can safely receive certain biologic drugs without allergic reactions, using skin tests to see how the body reacts. It may help find out if you are allergic to a biologic medicine you have taken before.
AngersAges 18 years+ - NCT07264803RecruitingPhase 2
Tumor testing to guide treatment for advanced cancers
This trial uses a patient's own tumor tissue to test which drugs might work best for cancers that have returned or not responded to previous treatments. It focuses on advanced gastric cancer and other solid tumors.
Jinan, ShandongAges 18–75 - NCT07514416RecruitingPhase 1
Safety study of LCFA-01 drug in healthy women
This study tests a new drug called LCFA-01 to make sure it's safe and works as expected in healthy women. The drug is being developed to treat bacterial vaginosis, a common vaginal infection.
Brisbane, QueenslandAges 18–40 - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT06907784Recruiting
Genetic testing before certain meds in hospital or clinic
This trial checks if genetic testing can help doctors pick safer drugs for you when you are in the hospital or visiting a clinic. If you qualify, you will give a cheek swab and be followed for about 12 weeks.
ClydebankAges 18 years+ - NCT07186842RecruitingPhase 1/Phase 2
Testing the safety of BNT329 for advanced CA19-9 positive tumors
This trial tests if the investigational drug BNT329 is safe and could help people with advanced solid tumors that make a marker called CA19-9. It is for those who have tried standard treatments and need new options.
Denver, ColoradoAges 18 years+ - NCT07220538RecruitingPhase 4
Ginkgo biloba for memory problems after a mild stroke
This trial tests whether adding ginkgo biloba extract tablets to standard stroke care helps improve memory and thinking in people who had a mild stroke. You may join if you are 55 or older, had a mild stroke in the last 1 to 2 weeks, and now have some cognitive difficulties.
AnyangAges 55 years+ - NCT06949865Recruiting
AI-enhanced levodopa challenge test for parkinsonism
This study uses artificial intelligence (AI) to improve a standard test for parkinsonism called the levodopa challenge test. It may help doctors better understand how your movement symptoms respond to levodopa, a common Parkinson's medication.
BeijingAges 50–75 - NCT05769023Enrolling by invitation
Pilot test targeting HIV prevention for people who inject drugs
This pilot program studies where HIV risk is highest and uses that information to decide how prevention efforts should be delivered. If you’ve used opioids recently and you inject drugs, you may be invited to participate to help reduce HIV risk.
Baltimore, MarylandAges 18 years+ - NCT07758907Enrolling by invitation
Testing a device that reads fingerprints for drug screening
This trial tests a new drug screening system that reads fingerprints to detect drugs in the body. It will check if certain medications interfere with the device's accuracy, which may lead to faster and easier drug testing in the future.
Marlton, New JerseyAges 18–55 - NCT07003295RecruitingPhase 2
Glofitamab for mantle cell lymphoma that returned after CAR-T
This trial tests a new drug, glofitamab, for mantle cell lymphoma that came back or didn’t respond after CAR-T cell therapy. It aims to see if glofitamab can shrink or control the lymphoma.
Duarte, CaliforniaAges 18 years+ - NCT05859334RecruitingPhase 2
Erdafitinib for brain tumors that came back or worsened
This Phase 2 study tests erdafitinib, a targeted anti-cancer medicine, for certain brain cancers that have returned or progressed after standard treatment. It may help if your tumor has a specific genetic change (FGFR-TACC fusion) that this drug is designed to attack.
Aurora, ColoradoAges 18 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
New Haven, ConnecticutAges 18 years+ - NCT06532279RecruitingPhase 2
Testing BMX-001 with chemoradiation for head and neck cancer
This trial tests whether adding BMX-001 (a drug that may protect healthy tissues) to standard chemoradiation can reduce side effects and improve outcomes for people with head and neck cancer. It's a randomized study, so you would have a 50/50 chance of getting BMX-001 or a placebo.
Gilbert, ArizonaAges 18 years+ - NCT06730555Recruiting
HIV and hepatitis C testing for people who inject drugs
This study works with syringe service programs to see if offering opt-out HIV and hepatitis C testing helps more people get screened and connected to care. It focuses on programs that do not already offer this testing and are in high-need areas.
Miami, FloridaAges 18 years+ - NCT06929533Recruiting
Genetic testing to guide mental health medication
This study tests if using genetic information can help doctors choose the right mental health medication or dose. It may help find treatments that work better with fewer side effects.
Winnipeg, ManitobaAges 18 years+ - NCT02738047Recruiting
PGx test to reduce medication side effects and repeat hospital visits
This trial checks whether using a genetic (DNA) medication test—done within the last 120 days—can help reduce bad medication reactions and prevent readmissions to the hospital. It may help people whose medications have caused side effects or did not work well.
York, PennsylvaniaAges 25 years+ - NCT06232044RecruitingPhase 1/Phase 2
Testing a new drug combo for returning multiple myeloma
This trial tests a combination of two approved drugs (lenalidomide and dexamethasone) plus an experimental drug (iberdomide) for people with multiple myeloma that has returned or stopped responding to treatment. It aims to see if this new combination can help control the disease.
Ames, IowaAges 18 years+ - NCT02693535RecruitingPhase 2
Match FDA cancer drugs to a tumor gene change
This trial tests FDA-approved cancer medicines in people with advanced cancer whose tumor has a specific gene or protein abnormality. It tries to see whether targeting that tumor “fingerprint” can help when standard treatments no longer work.
Birmingham, AlabamaAges 12 years+ - NCT04154553Recruiting
Genetic testing to prevent bad drug reactions or treatment failures
This study looks at whether a person’s genetic makeup can help choose safer medicines or improve how well treatment works. You may be asked for testing if you’ve had a bad reaction or treatment failure, or if you’re starting a new medicine that is known to be affected by genetics.
BaselAges 2 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Birmingham, AlabamaAges 18 years+
Common questions
- Are there clinical trials studying Test Drug?
- Yes. Clin2 currently lists 124 recruiting studies that include Test Drug, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Test Drug trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Test Drug an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Test Drug or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.